Johnson & Johnson (JNJ)
Develops prescription medicines and cardiovascular, surgical, orthopaedic and vision technologies.
Something off on this page? Send us feedback.
Earns revenue through two global segments: Innovative Medicine sells prescription therapies, while MedTech supplies cardiovascular, surgical, orthopaedic and vision products. Product approvals and patent cycles shape the medicine portfolio, and Orthopaedics is slated for separation.
Develops prescription medicines through Innovative Medicine and medical technologies through MedTech for healthcare systems worldwide. The medicine portfolio spans oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolic conditions; DARZALEX is its largest product franchise.
Sells electrophysiology, heart-support, circulatory-restoration and neurovascular devices, plus surgical systems, orthopaedics, ACUVUE contact lenses and TECNIS intraocular lenses. Internal research, collaborations, licensing and acquisitions replenish the portfolio, while global manufacturing and specialist distribution place products with hospitals, clinicians, wholesalers and retailers.
Results depend on clinical development, regulatory approvals, patent protection, reimbursement and product safety. Patent losses can quickly erode medicine sales, and talc litigation remains unresolved. Orthopaedics remains inside MedTech while a separation into a standalone DePuy Synthes is planned.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 10, 2026 | HSBC | Reiterate | Rating: —Target: $290 | Target: $320 |
| Sep 2, 2026 | UBS | Reiterate | Rating: —Target: $214 | Target: $320 |
| Aug 6, 2026 | Guggenheim | Reiterate | Rating: —Target: $270 | Target: $287 |
| Aug 3, 2026 | Raymond James | Target | Target: $265 | Target: $280 |
| Aug 3, 2026 | Wells Fargo | Reiterate | Rating: —Target: $272 | Target: $282 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 28, 2026Cash & short-term investments $20.76B · Total debt $49.04B · Total assets $201.06B · Shareholders' equity $84.97B
- Revenue
- $25.31B
- Operating income
- $7.17B
- Net income
- $5.53B
HistoryDividendAnnual yield
| Institutions | 75.41% | 1.82B shares | |
|---|---|---|---|
| 4,804 holders · as of Jun 30, 2026 | |||
| Insiders | 0.04% | 884.0K shares | |
| 15 holders · as of Sep 4, 2026 | |||
| Other | 24.55% | 591.64M shares | |
| remainder | |||
2.41B company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.80% | 212.10M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.52% | 157.23M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.55% | 133.78M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 2.67% | 64.37M | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 2.45% | 59.09M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 2, 2026 | Timothy Schmid | officer: EVP, WW Chair, MedTech | −22,527 | $274.74 |
| Aug 17, 2026 | Jennifer L. Taubert | officer: EVP, WWC. Innovative Medicine | −15,000 | $263.36 |
| Aug 13, 2026 | Joaquin Duato | director, officer: CEO and Chairman of the Board | −123,291 | $261.17 |
| Aug 6, 2026 | Elizabeth Forminard | officer: EVP, Chief Legal Officer | −15,918 | $257.00 |
| Aug 5, 2026 | Joaquin Duato | director, officer: CEO and Chairman of the Board | −48,480 | $258.15 |
- AbbVie
Head-to-head in immunology and hematology-oncology.
- Merck
Largest pharma rival by revenue; Keytruda contests the oncology space.
- Medtronic
#1 global MedTech; contests cardiovascular, spine, and surgical with JNJ MedTech.
- Bristol-Myers Squibb
Myeloma and hematology head-to-head; overlaps in immunology and CAR-T.
- Stryker
Orthopaedic market leader challenging DePuy Synthes across joints, trauma, and spine.
- Boston Scientific
Fast-growing MedTech rival taking EP share from JNJ’s Biosense Webster.
- Abbott
Cardiovascular and electrophysiology rival challenging JNJ’s EP market position.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Johnson & Johnson | $267.82 | −0.61% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| AbbVie | $265.98 | +0.57% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Merck | $152.18 | +1.79% | $369.24B | 119.6 | 17.6 | 5.6 | +5.1% |
| Medtronic | $91.64 | −0.13% | $117.44B | 22.6 | 15.3 | 3.1 | +13.7% |
| Bristol-Myers Squibb | $62.70 | +0.13% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Stryker | $276.42 | +0.81% | $105.11B | 28.4 | 17.3 | 4.1 | +9.4% |
| Boston Scientific | $44.64 | +2.10% | $64.98B | 17.8 | 13.6 | 3.1 | +7.5% |
| Abbott | $104.01 | +1.00% | $178.18B | 33.1 | 17.9 | 3.8 | +13.0% |
| Median | 28.4 | 17.3 | 3.8 | +9.4% |